Pharsight

Iluvien patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6217895 ALIMERA SCIENCES INC Method for treating and/or preventing retinal diseases with sustained release corticosteroids
Mar, 2019

(5 years ago)

US6548078 ALIMERA SCIENCES INC Method for treating and/or preventing retinal diseases with sustained release corticosteroids
Mar, 2019

(5 years ago)

US8252307 ALIMERA SCIENCES INC Method for treating and/or preventing retinal diseases with sustained release corticosteroids
Jun, 2019

(4 years ago)

US6375972 ALIMERA SCIENCES INC Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
Apr, 2020

(4 years ago)

US8871241 ALIMERA SCIENCES INC Injectable sustained release delivery devices
Aug, 2027

(3 years from now)

Iluvien is owned by Alimera Sciences Inc.

Iluvien contains Fluocinolone Acetonide.

Iluvien has a total of 5 drug patents out of which 4 drug patents have expired.

Expired drug patents of Iluvien are:

  • US6217895
  • US6548078
  • US8252307
  • US6375972

Iluvien was authorised for market use on 26 September, 2014.

Iluvien is available in implant;intravitreal dosage forms.

Iluvien can be used as treatment of diabetic macular edema.

The generics of Iluvien are possible to be released after 12 August, 2027.

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Sep 26, 2017

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using FLUOCINOLONE ACETONIDE ingredient

Market Authorisation Date: 26 September, 2014

Treatment: Treatment of diabetic macular edema

Dosage: IMPLANT;INTRAVITREAL

More Information on Dosage

ILUVIEN family patents

Family Patents